Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 74711-43-6
2. 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic Acid
3. 89482-00-8
4. Soleton
5. Cn-100
6. Soreton
7. Peon
8. Zaltoprofen [inn]
9. Cn 100
10. Zaltoprofene
11. Zaltoprofeno
12. Zaltoprofenum
13. Zaltoprofen [inn:jan]
14. Zaltoprofene [inn-french]
15. Zaltoprofenum [inn-latin]
16. 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic Acid
17. Zaltoprofeno [inn-spanish]
18. 10,11-dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic Acid
19. H8635ng3py
20. Cn100
21. Zaltoprofen (+-)-
22. 2-(6-oxo-5h-benzo[b][1]benzothiepin-3-yl)propanoic Acid
23. Zaltoprofen Sodium Salt
24. Ncgc00183878-01
25. Dsstox_cid_29002
26. Dsstox_rid_83267
27. Dsstox_gsid_49076
28. Zaltoprofen (unspecified)
29. 10,11-dihydro-alpha-methyl-10-oxodibenzo[b,f]thiepin-2-acetic Acid
30. 2-(10-oxo-10,11-dihydrodibenzo-[b,f]thiepin-2-yl)propanoic Acid
31. Smr003500719
32. Cas-74711-43-6
33. Einecs 277-973-5
34. Unii-h8635ng3py
35. (+-)-10,11-dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic Acid
36. Peon (tn)
37. Zaltoprofen [mi]
38. Zaltoprofen [jan]
39. (+-)-2-(10,11-dihydro-10-oxodibenzo(b,f)thiepin-2-yl)propionic Acid
40. Zaltoprofen (jp17/inn)
41. Zaltoprofen [mart.]
42. Zaltoprofen [who-dd]
43. Mls004774050
44. Mls006010214
45. Schembl124047
46. Amy421
47. Chembl1765291
48. Dtxsid0049076
49. Chebi:32306
50. Hms3656j14
51. Hms3744o11
52. Hms3885e03
53. Bcp02387
54. Hy-b0619
55. Tox21_113634
56. 10,11-dihydro-alpha-methyl-10-oxo-dibenzo[b,f]thiepin-2-acetic Acid
57. Mfcd00864323
58. S3008
59. Zc-102
60. Akos015895991
61. Dibenzo(b,f)thiepin-2-acetic Acid, 10,11-dihydro-alpha-methyl-10-oxo-
62. Tox21_113634_1
63. Ccg-267450
64. Db06737
65. Gs-3949
66. Ncgc00263585-01
67. Ncgc00263585-04
68. Ac-32652
69. Ft-0630837
70. Ft-0656731
71. Sw219801-1
72. Z0021
73. D01547
74. Ab01565848_02
75. 711z436
76. A838204
77. F0001-2421
78. 2-(6-oxo-5a,6-dihydrodibenzo[b,f]thiepin-3-yl)propanoic Acid
79. 10,11-dihydro-alpha-methyl-10-oxo-dibenzo[b,f]thiepin-2-aceticacid
80. 2-(10,11-dihydro-10-oxodibenzo [b,f] Thiepin-2-yl)propionic Acid
81. 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)-propionic Acid
82. 2-(10-oxo-10,11-dihydro-dibenzo[b,f]thiepin-2-yl)-propionic Acid
83. (alphar)-10,11-dihydro-alpha-methyl-10-oxodibenzo[b,f]thiepin-2-acetic Acid
84. (alphas)-10,11-dihydro-alpha-methyl-10-oxodibenzo[b,f]thiepin-2-acetic Acid
85. 1166864-09-0
86. 2-{10-oxo-2-thiatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-6-yl}propanoic Acid
Molecular Weight | 298.4 g/mol |
---|---|
Molecular Formula | C17H14O3S |
XLogP3 | 3.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Exact Mass | 298.06636548 g/mol |
Monoisotopic Mass | 298.06636548 g/mol |
Topological Polar Surface Area | 79.7 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 422 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Zaltoprofen has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoyloxy]oxane-2-carboxylic acid, 10-hydroxy-zaltoprofen, and Zaltoprofen S-oxide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
ABOUT THIS PAGE
A Zaltoprofen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zaltoprofen, including repackagers and relabelers. The FDA regulates Zaltoprofen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zaltoprofen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Zaltoprofen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Zaltoprofen supplier is an individual or a company that provides Zaltoprofen active pharmaceutical ingredient (API) or Zaltoprofen finished formulations upon request. The Zaltoprofen suppliers may include Zaltoprofen API manufacturers, exporters, distributors and traders.
click here to find a list of Zaltoprofen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Zaltoprofen Drug Master File in Japan (Zaltoprofen JDMF) empowers Zaltoprofen API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Zaltoprofen JDMF during the approval evaluation for pharmaceutical products. At the time of Zaltoprofen JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Zaltoprofen suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Zaltoprofen Drug Master File in Korea (Zaltoprofen KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Zaltoprofen. The MFDS reviews the Zaltoprofen KDMF as part of the drug registration process and uses the information provided in the Zaltoprofen KDMF to evaluate the safety and efficacy of the drug.
After submitting a Zaltoprofen KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Zaltoprofen API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Zaltoprofen suppliers with KDMF on PharmaCompass.
A Zaltoprofen written confirmation (Zaltoprofen WC) is an official document issued by a regulatory agency to a Zaltoprofen manufacturer, verifying that the manufacturing facility of a Zaltoprofen active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Zaltoprofen APIs or Zaltoprofen finished pharmaceutical products to another nation, regulatory agencies frequently require a Zaltoprofen WC (written confirmation) as part of the regulatory process.
click here to find a list of Zaltoprofen suppliers with Written Confirmation (WC) on PharmaCompass.
Zaltoprofen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zaltoprofen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zaltoprofen GMP manufacturer or Zaltoprofen GMP API supplier for your needs.
A Zaltoprofen CoA (Certificate of Analysis) is a formal document that attests to Zaltoprofen's compliance with Zaltoprofen specifications and serves as a tool for batch-level quality control.
Zaltoprofen CoA mostly includes findings from lab analyses of a specific batch. For each Zaltoprofen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zaltoprofen may be tested according to a variety of international standards, such as European Pharmacopoeia (Zaltoprofen EP), Zaltoprofen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zaltoprofen USP).
LOOKING FOR A SUPPLIER?